CN103054025A - Health-care food composition for preventing and treating prostate disease - Google Patents
Health-care food composition for preventing and treating prostate disease Download PDFInfo
- Publication number
- CN103054025A CN103054025A CN2013100030375A CN201310003037A CN103054025A CN 103054025 A CN103054025 A CN 103054025A CN 2013100030375 A CN2013100030375 A CN 2013100030375A CN 201310003037 A CN201310003037 A CN 201310003037A CN 103054025 A CN103054025 A CN 103054025A
- Authority
- CN
- China
- Prior art keywords
- health
- preventing
- food composition
- care food
- sterol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a health-care food composition for preventing and treating prostate diseases, and a preparation method of the composition. The composition comprises the following ingredients by weight: 5.00-30.00% of sterol ferulic acid ester, 5.0-20.00% of free sterol, 10.00-30.00% of vitamin E and 40.00-80.00% of vegetable oil; the ingredients are weighed and compounded according to the ratio, mixed, uniformly stirred and made into soft capsules. The health-care food composition for preventing and treating prostate diseases has the functions of preventing and treating diseases such as chronic abacterial prostatitis and prostate tumor, is safe, has no side effects and is convenient to take; and in addition, the health-care food composition for preventing and treating prostate diseases is simple in production process and easy to popularize.
Description
Technical field
The present invention relates to field of health care food, particularly prevent and treat health-care food composition of prostatic disorders and preparation method thereof.
Background technology
Prostatitis syndrome (Prostatitis Syndrome, PS) is the common frdquently encountered disease of male urinary system, and prostate cancer (Prostate Cancer, PCa) is to threaten one of modal cancerous swelling of men's health.Prostate is the genital orgnas,male, and the region of anatomy is special, and medicine is difficult to enter and towards periphery diffusion, and it is very thorny that integrative therapy is all felt.
For the treatment of PS, except physical treatment, massage of prostate, drug therapy is indispensable at present.Medicine comprises antibiotic, alpha-blocking agent and non-steroidal anti-inflammatory agent etc.Although medicine is varied, curative effect is all not satisfactory, and recurrence rate is higher, and western medicine all has certain side effect (Chronic Prostatitis/Chronic Pelvic Pain Syndrome, Urol ClinN Am, 2008,35:81-89; The present situation of prostatitis treating, Mountain Western Medicine S University's journal, 2007,38 (5): 463-466).
For the treatment of PCa, radical correction is prefered method, but can only cure the early stage PCa that is confined in the coating.And, because prostate position is hidden, atypical symptoms, the patient often has been patients with terminal when medical.In, late period PCa multiselect Androgen deprivation therapy.But, Androgen deprivation therapy can only provide temporary transient alleviation usually, nearly all patient can be recurred and make progress and is more refractory and more pernicious androgen independence PCa (Androgen deprivation therapy for prostatecancer does not increase cardiovascular morality in the long term, Oncology, 2012,82:56-58).
Publication number discloses a kind of health food of preventing and treating prostatic disorders and preparation method thereof for the Chinese patent literature of " CN 101019986A ", with Typhonium flagelliforme (Lodd.) Blume, evodia rutaecarpa, Niu Xi, saline cistanche, barrenwort, the red sage root, faenum graecum, pyrola, the leek seed carries out respectively super-micro wall-broken and pulverizes, pulverizing medium particle diameter is below the 10um, the breaking-wall cell rate is more than or equal to 95%, the Typhonium flagelliforme (Lodd.) Blume of afterwards super-micro wall-broken being pulverized, evodia rutaecarpa, Niu Xi, saline cistanche, barrenwort, the red sage root, faenum graecum, pyrola is respectively-7 ℃～-15 ℃ lower cryogenic freezings, mix after freezing 40～55 hours, stir, make mixture 1; In the leek seed that super-micro wall-broken is pulverized, add grape seed extract and fully mix, make mixture 2, afterwards two kinds of mixtures are put into together and fully mixed, and carry out low temperature drying at-27 ℃～-46 ℃, add afterwards propolis, be mixed and made into product.Disclosed health food raw materials costliness and its preparation method complexity of preventing and treating prostatic disorders of this patent documentation.
Therefore, research and development have no side effect, taking convenience, preparation are simple, the health food of preventing and treating prostatic disorders that be applicable to long-term taking is significant.
Summary of the invention
The object of the present invention is to provide a kind ofly to have no side effect, prepare simple, taking convenience and be applicable to having of long-term taking and prevent and treat health-care food composition of prostatic disorders function and preparation method thereof.
A kind of health-care food composition of preventing and treating prostatic disorders, by weight percentage, said composition comprises:
Sterol ferulic acid ester 5.00-30.00%;
Free sterol 5.00-20.00%;
Vitamin E 10.00-30.00%;
Vegetable oil 40.00-80.00%.
The health-care food composition of preventing and treating prostatic disorders of the present invention can also add the additives such as flavor enhancement, food coloring.
Sterol is the material that a class has physiologically active, and aspect medical, it can reduce the cholesterol in the body, and repair tissue is arranged, and suppresses the effect of tumor growth, can be used for preventing and treating prostatitis, prostate cancer.
Sterol ferulic acid ester of the present invention is that hydroxyl on the sterol C3 position is combined the sterol derivative that dehydration forms with forulic acid.The sterol ferulic acid ester has the structure of sterol and forulic acid concurrently, has better lipophilicity, the easier biomembrane lipid bilayer that sees through, so sterol ferulic acid ester specific ionization sterol and forulic acid have more remarkable biological effect.
Vitamin E can effectively be cleared up oxygen radical in the human body, improves body endurance, strengthen immunologic function, and significantly anti-aging, diseases prevention, protective effect on cancer risk are arranged; Can reduce cholesterol, improve microcirculation in human body; These functions all help to prevent and treat prostatic disorders.
The effect of vegetable oil in the health-care food composition that prevents prostatic disorders of the present invention is to make described sterol ferulic acid ester, free sterol and vitamin E to be dispersed in the vegetable oil, and be easier of Cell uptake.
Preferably, the described health-care food composition of preventing and treating prostatic disorders, by weight percentage, said composition comprises:
Sterol ferulic acid ester 20.00-25.00%;
Free sterol 10.00-15.00%;
Vitamin E 20.00-25.00%;
Vegetable oil 45.00-50.00%.
As preferably, in the health-care food composition of preventing and treating prostatic disorders of the present invention the sterol ferulic acid ester be forulic acid and phytosterol in conjunction with ester; Described free sterol is phytosterol.
Phytosterol has stronger anti-oxidant, antiinflammatory action to human body, has can suppress human body to effects such as the absorption of cholesterol, the katabolism of promotion cholesterol, the biochemistry of inhibition cholesterol synthesize; And phytosterol to the treatment prostatic disorders, suppress hypertrophy of the prostate, alleviate the hyperplasia of prostate symptom, prevent and treat the prostatic disorders such as prostate cancer and have good efficacy.
As further preferred, described sterol ferulic acid ester is one or several in sitosterol ferulic acid ester, stigmasteryl ferulate, brassicasterol ferulic acid ester, 24-methyl cholane alcohol ferulic acid ester, 24-methine cholane alcohol ferulic acid ester, the cycloartenyl ferulate; Described free sterol is one or several in sitosterol, stigmasterol, brassicasterol, campesterol, ergosterol, the paddy alkanol.Above-mentioned sterol ferulic acid ester and free sterol are natural materials, have effect and the safe without toxic side effect of the prostatic disorders of preventing and treating.More preferably, described sterol ferulic acid ester is oryzanol, and oryzanol is the sterol Gamma OZ, and is cheap and easy to get.
Described vegetable oil is camellia oil, olive oil or corn oil.Camellia oil, olive oil or corn oil are pure natural plant oil commonly used, and safety has no side effect.
As preferred version, by weight percentage, the health-care food composition of preventing and treating prostatic disorders comprises:
Oryzanol 20.00-25.00%;
Sitosterol 10.00-15.00%;
Vitamin E 20.00-25.00%;
Olive oil 45.00-50.00%.
By weight percentage, oryzanol is that 20.00-25.00%, sitosterol are that 10.00-15.00%, vitamin E are that 20.00-25.00%, olive oil are that the health-care food composition of preventing and treating prostatic disorders of 45.00-50.00% is prevented and treated the effective of chronic prostatitis.
As another kind of preferred version, by weight percentage, the described health-care food composition of preventing and treating prostatic disorders comprises:
Oryzanol 20.00-25.00%;
Stigmasterol 10.00-15.00%;
Vitamin E 20.00-25.00%;
Camellia oil 45.00-50.00%.
By weight percentage, oryzanol is that 20.00-25.00%, stigmasterol are that 10.00-15.00%, vitamin E are that 20.00-25.00%, camellia oil are that the health-care food composition of preventing and treating prostatic disorders of 45.00-50.00% is prevented and treated the effective of prostate cancer.
The described preparation method who prevents and treats the health-care food composition of prostatic disorders may further comprise the steps:
1) weighing is composite in proportion with sterol ferulic acid ester, free sterol, vitamin E and vegetable oil;
2) raw material is mixed and stir;
3) soft capsule is made in can.
Adult male is taken 3 times every day, and each 500mg-1000mg (soft capsule of 1-2 grain 500mg/ grain) takes more than one month continuously, can significantly prevent and treat generation and the development of the diseases such as prostatitis, prostate cancer.
The health-care food composition of preventing and treating prostatic disorders of the present invention has the effect of the diseases such as control chronic non-bacterial prostatitis, prostate cancer, and safety has no side effect and taking convenience; Each stock yard has synergistic function, can produce by different mechanism and prevent and treat the effect of the diseases such as prostatitis, prostate cancer, and its effect significantly is better than sterol ferulic acid ester or the free sterol with dosage.Health-care food composition production technology of preventing and treating prostatic disorders of the present invention is simple in addition, is easy to promote.
The specific embodiment
According to each the raw material proportioning in the table 1, sterol ferulic acid ester, free sterol, vitamin E and vegetable oil weighing is composite, then mix and stir, soft capsule is made in last can, 500 milligrams of every soft capsules.Preparation Example 1～11 have a health-care food composition soft capsule PS-1～PS-11 that prevents and treats the prostatic disorders effect.
Oryzanol is the sterol Gamma OZ, white powder, and sterol ferulic acid ester total amount 〉=99% is produced by Hangzhou Xin Wufeng pharmaceutcal corporation, Ltd of East China Pharmaceutical Group Co., Ltd;
Sitosterol ferulic acid ester, stigmasteryl ferulate, beans alkanol ferulic acid ester, brassicasterol ferulic acid ester, cycloartenyl ferulate, 24-methyl cholane alcohol ferulic acid ester, 24-methine cholane alcohol forulic acid are that " CN 102421788A ", name are called the disclosed method self-control of the patent of invention gained of " for the preparation of the method for phytosterol ferulic acid ester " according to publication number;
Phytosterol mixture (total sterol content 〉=95%) is produced by Xi'an Hai Sifu bio tech ltd;
Cupreol (purity 〉=98%), stigmasterol (purity 〉=95%), paddy alkanol (purity 〉=98%), campesterol (purity 〉=98%), brassicasterol (purity 〉=98%), ergosterol (purity 〉=95%), produced by sky, Shanghai letter bio tech ltd;
Camellia oil is produced by Suichang of Zhejiang Province your tea oil Co., Ltd of leading a happy family life;
Corn oil is produced by western king's food limited company;
Olive oil is produced by the happy olive oil in rural area, Foochow trade Co., Ltd.
Table 1 is prevented and treated the health-care food composition soft capsule raw material proportioning of prostatic disorders
Effect assessment 1 health-care food composition of the present invention is to prostatitic preventive and therapeutic effect
Injection of prostate proinflammatory agent to rat is set up prostatitis rat model, then to the rat oral gavage administration of successful modeling; Divide into groups according to administration kind difference: model group (camellia oil), oryzanol group, cupreol group, PS-1 sample sets, PS-4 sample sets.The health-care food composition PS-1, the PS-4 that prevent and treat prostatic disorders by camellia oil, oryzanol, cupreol and embodiment 1, embodiment 4 carry out effect assessment to the prostatitis rat model influence degree, and concrete operations are as follows:
50 of SD rats, male, by the body weight random packet, 10 every group, be divided into 5 groups: model group (camellia oil), oryzanol group, cupreol group, PS-1 sample sets, PS-4 sample sets.
With the rat etherization, face upward the position and fix lower abdomen cropping, routine disinfection.Under the aseptic condition, about lower abdomen midsection 1.5cm, through abdominal cavity, mention bladder and both sides seminal vesicle, exposure invests the lateral lobe of prostate gland of seminal vesicle inboard, respectively injects proinflammatory agent (25% XIAOZHILING ZHUSHEYE is with the preparation of 0.9%NaCl parenteral solution) 0.1mL at two lateral lobes, drip antibiotic solution in the abdominal cavity in case infect, sew up respectively muscle, skin.
Beginning administration in the 2nd day after the operation, dosage regimen is:
Model group: camellia oil, 250mg/kg; Oryzanol group: oryzanol, 250mg/kg; Cupreol group: cupreol, 250mg/kg; PS-1 sample sets: PS-1 soft capsule, 500mg/kg (being equivalent to oryzanol, cupreol and vitamin E total amount 250mg/kg); PS-4 sample sets: PS-4 soft capsule, 455mg/kg (being equivalent to oryzanol, stigmasterol and vitamin E total amount 250mg/kg).
Gastric infusion, every day 1 time, continuous 4 weeks.The outward appearance situations such as the food ration of observation animal, amount of drinking water, spirit, hair, take by weighing weekly body weight, and according to body weight adjustment dosage, 24h puts to death rat after the last administration, the prostatic form of anatomic observation, size, with the situation such as surrounding tissue adhesion, each leaf prostate of anatomical isolation is weighed, and calculates organ index.
The rat prostate weight in wet base of each grouping of table 2 prostatitis rat model and prostate index (n=10, x ± SD)
Annotate: adopt Duncan ' s multiple range test methods analyst, the different letter representation significant differences (p＜0.05) of same row
After the xiaozhiling injection modeling, model group rat prostate tissue produces oedema and inflammatory cell infiltration phenomenon, and showing as weight of prostate increases; With model group relatively, oryzanol, cupreol, PS-1, PS-4 all can reduce lateral lobe prostate index and total body of gland prostate index to some extent suppressing to some extent the increase of lateral lobe of prostate gland and gross weight, the results are shown in Table 2; PS-1, PS-4 effect all are better than with the oryzanol group of dosage or cupreol group, and the inhibition of PS-1 is better than PS-4.
Effect assessment 2 health-care food compositions of the present invention are to the preventive and therapeutic effect of prostate cancer
Set up the model of human prostate carcinoma of BALB/c (nu/nu) nude mice, then to BALB/c (nu/nu) the nude mice gastric infusion of successful modeling; Difference according to the administration kind is divided into groups: model group (olive oil), oryzanol group, cupreol group, PS-8 sample sets, PS-9 sample sets.The health-care food composition PS-8, the PS-9 that prevent and treat prostatic disorders by olive oil, oryzanol, cupreol and embodiment 8, embodiment 9 carry out effect assessment to the model of human prostate carcinoma influence degree of BALB/c (nu/nu) nude mice, and concrete operations are as follows:
50 of BALB/c (nu/nu) nude mices, male, age in 6-7 week, weight 22～30g.The DU145 cell of taking the logarithm growth period after 0.25% trypsinization, makes 1 * 10
6The cell suspension of/0.1mL connect plant respectively in back, 50 nude mice right sides subcutaneous, set up human prostata cancer nude mice by subcutaneous transplantable tumor animal model, nude mice random packet with successful modeling, every group 8, be divided into 5 groups: model group (olive oil), oryzanol group, cupreol group, PS-8 sample sets, PS-9 sample sets.
The 2nd day beginning gastric infusion after the injection, dosage regimen:
Model group: olive oil, 250mg/kg; Oryzanol group: oryzanol, 250mg/kg; Cupreol group: cupreol, 250mg/kg; PS-8 sample sets: PS-8 soft capsule, 500mg/kg (being equivalent to oryzanol, brassicasterol and vitamin E total amount 250mg/kg); PS-9 sample sets: PS-9 soft capsule, 455mg/kg (being equivalent to oryzanol, phytosterol and vitamin E total amount 250mg/kg).
Administration every day 1 time, continuous 6 weeks.
Behind the last medication 24h, the cervical vertebra dislocation method is put to death, and becomes celestial and observes the growing state of lotus knurl position tumour, and get tumour, detects gross tumor volume and weight, calculates inhibition rate of tumor growth.Tumour inhibiting rate %=(model control group tumor weight-administration group tumor weight) * 100%/model control tumor weight.
BALB/c (nu/nu) nude mice body weight of each grouping of table 3 model of human prostate carcinoma, knurl weight and tumour inhibiting rate (n=8,
Annotate: adopt Duncan ' s multiple range test methods analyst, the different letter representation significant differences (p＜0.05) of same row
Compare with model group, oryzanol, cupreol, PS-8, PS-9 all can suppress to some extent the heavy increase of BALB/c (nu/nu) nude mice body weight and knurl; The tumour inhibiting rate of oryzanol, cupreol, PS-8, PS-9 reaches respectively 43.6,43.0,56.2 and 64.7%; The heavy effect of PS-8, PS-9 inhibition prostate tumor is better than oryzanol group or the cupreol group with dosage, and the inhibition of PS-9 is better than PS-8, the results are shown in Table 3.
Claims (10)
1. a health-care food composition of preventing and treating prostatic disorders is characterized in that, by weight percentage, said composition comprises:
Sterol ferulic acid ester 5.00-30.00%;
Free sterol 5.00-20.00%;
Vitamin E 10.00-30.00%;
Vegetable oil 40.00-80.00%.
2. the health-care food composition of preventing and treating prostatic disorders as claimed in claim 1 is characterized in that, by weight percentage, said composition comprises:
Sterol ferulic acid ester 20.00-25.00%;
Free sterol 10.00-15.00%;
Vitamin E 20.00-25.00%;
Vegetable oil 45.00-50.00%.
3. the health-care food composition of preventing and treating prostatic disorders as claimed in claim 1 is characterized in that, described sterol ferulic acid ester be forulic acid and phytosterol in conjunction with ester.
4. the health-care food composition of preventing and treating prostatic disorders as claimed in claim 3, it is characterized in that described sterol ferulic acid ester is one or several in sitosterol ferulic acid ester, stigmasteryl ferulate, brassicasterol ferulic acid ester, 24-methyl cholane alcohol ferulic acid ester, 24-methine cholane alcohol ferulic acid ester, the cycloartenyl ferulate.
5. the health-care food composition of preventing and treating prostatic disorders as claimed in claim 3 is characterized in that, described sterol ferulic acid ester is oryzanol.
6. the health-care food composition of preventing and treating prostatic disorders as claimed in claim 1 is characterized in that, described free sterol is phytosterol.
7. the health-care food composition of preventing and treating prostatic disorders as claimed in claim 6 is characterized in that, described free sterol is one or several in sitosterol, stigmasterol, brassicasterol, campesterol, ergosterol, the paddy alkanol.
8. the health-care food composition of preventing and treating prostatic disorders as claimed in claim 1 is characterized in that, described vegetable oil is camellia oil, olive oil or corn oil.
9. the health-care food composition of preventing and treating prostatic disorders as claimed in claim 1 is characterized in that, by weight percentage, said composition comprises:
Oryzanol 20.00-25.00%;
Sitosterol 10.00-15.00%;
Vitamin E 20.00-25.00%;
Olive oil 45.00-50.00%.
10. the health-care food composition of preventing and treating prostatic disorders as claimed in claim 1 is characterized in that, by weight percentage, said composition comprises:
Oryzanol 20.00-25.00%;
Stigmasterol 10.00-15.00%;
Vitamin E 20.00-25.00%;
Camellia oil 45.00-50.00%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013100030375A CN103054025A (en) | 2013-01-04 | 2013-01-04 | Health-care food composition for preventing and treating prostate disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013100030375A CN103054025A (en) | 2013-01-04 | 2013-01-04 | Health-care food composition for preventing and treating prostate disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103054025A true CN103054025A (en) | 2013-04-24 |
Family
ID=48097169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013100030375A Pending CN103054025A (en) | 2013-01-04 | 2013-01-04 | Health-care food composition for preventing and treating prostate disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103054025A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103876157A (en) * | 2014-04-14 | 2014-06-25 | 哈尔滨工业大学 | Soyasterol tablet with health care function and preparation method of soyasterol tablet |
| CN112715938A (en) * | 2020-12-28 | 2021-04-30 | 完美（中国）有限公司 | Composition for inhibiting prostatic hyperplasia |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1720030A (en) * | 2002-12-06 | 2006-01-11 | 帝斯曼知识产权资产管理有限公司 | The new purposes of lycopene |
| CN101039585A (en) * | 2004-08-10 | 2007-09-19 | 酶学技术有限公司 | Mixture of phytosterol ester(s) and 1,3-diglyceride(s) for use in the treatment of medical conditions |
| CN101570560A (en) * | 2008-04-30 | 2009-11-04 | 上海医药工业研究院 | Two sterol derivatives, separation and extraction method thereof and application thereof in preventing and treating prostatoplasia diseases |
| CN101897912A (en) * | 2010-07-27 | 2010-12-01 | 浙江大学 | Bamboo shoot sterol soft capsules and application thereof |
-
2013
- 2013-01-04 CN CN2013100030375A patent/CN103054025A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1720030A (en) * | 2002-12-06 | 2006-01-11 | 帝斯曼知识产权资产管理有限公司 | The new purposes of lycopene |
| CN101039585A (en) * | 2004-08-10 | 2007-09-19 | 酶学技术有限公司 | Mixture of phytosterol ester(s) and 1,3-diglyceride(s) for use in the treatment of medical conditions |
| CN101570560A (en) * | 2008-04-30 | 2009-11-04 | 上海医药工业研究院 | Two sterol derivatives, separation and extraction method thereof and application thereof in preventing and treating prostatoplasia diseases |
| CN101897912A (en) * | 2010-07-27 | 2010-12-01 | 浙江大学 | Bamboo shoot sterol soft capsules and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 姚惠源: "《谷物加工工艺学》", 30 July 1999, 中国财政经济出版社 * |
| 章宇等: "植物甾醇及甾烷醇的生理代谢调节功能及其机制研究进展", 《中草药》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103876157A (en) * | 2014-04-14 | 2014-06-25 | 哈尔滨工业大学 | Soyasterol tablet with health care function and preparation method of soyasterol tablet |
| CN112715938A (en) * | 2020-12-28 | 2021-04-30 | 完美（中国）有限公司 | Composition for inhibiting prostatic hyperplasia |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wong et al. | Pomegranate bioactive constituents target multiple oncogenic and oncosuppressive signaling for cancer prevention and intervention | |
| JP5345778B2 (en) | Use of pregnane glycosides in the treatment / management of obesity, obesity related disorders, and other disorders | |
| US7390514B2 (en) | Herbal composition for treatment and maintenance of hormone dependent conditions, osteoporosis, circulatory conditions, and for use as an immunostimulant | |
| CN103054025A (en) | Health-care food composition for preventing and treating prostate disease | |
| US7368134B2 (en) | Herbal composition for treatment and maintenance of hormone dependent conditions and circulatory conditions, and immunostimulation | |
| CN102631409B (en) | Health-care medicine formula with functions of enhancing immunity, alleviating physical fatigue and resisting tumor | |
| CN104815014A (en) | Application of polygonum cuspidatum in preparation for medicine for preventing and treating ionization radiation-induced intestinal injuries | |
| CN104435544A (en) | Traditional Chinese medicine oral liquid for treating leukemia through being cooperated with chemotherapy and preparation method thereof | |
| CN104000863A (en) | Medicinal composition for treating malignant tumor accompanied with gall-stone and preparation method and medical application thereof | |
| CN100531791C (en) | Antineoplastic, anti-cancer drugs | |
| CN109731019B (en) | A composition with chemotherapy synergistic effect comprises components, preparation and application | |
| CN104095904B (en) | A kind of pharmaceutical composition for treating courage relevant disease, preparation method and its usage | |
| CN106617053A (en) | Healthcare food for preventing and treating prostatitis and prostatic hyperplasia and preparation method thereof | |
| CN107335011B (en) | External traditional Chinese medicine compound preparation for treating cancer pain | |
| CN102258602B (en) | Chinese medicinal composition for treating rheumatism and rheumatoid and preparation method thereof | |
| CN100556448C (en) | Chinese medicine pharmaceutical composition of a kind of inhibition and treatment tumor and its production and application | |
| CN1287841C (en) | Method for preparing anti-cancer traditional Chinese medicine containing Mingri leaf | |
| CN112656887B (en) | Traditional Chinese medicine composition with anti-inflammatory and antioxidant functions, preparation and preparation method thereof | |
| Shafi | GREEN BLOOD THERAPY IN MODERN MEDICINE. | |
| CN105816862A (en) | Application of ulinastatin in preparation of drugs for treating prostatic cancer | |
| CN104491263A (en) | Medicine capable of promoting blood circulation to remove blood stasis for esophagus cancer and preparation method of medicine | |
| Tu et al. | Anti-inflammatory effects of a Chinese herbal tea, Shangqingyin, in mice and rats | |
| CN104474131B (en) | It is a kind of to be used to treat the medicine of bone amount reduction and osteoporosis caused by hepatopathy | |
| CN116983348A (en) | Traditional Chinese medicine composition for inhibiting bone cancer pain and preparation and application thereof | |
| EP3914237A1 (en) | Olive fruit extract suitable for reducing body-mass index and visceral fat in overweight subjects |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130424 |